Compare ACMR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | CRSP |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.8B |
| IPO Year | 2017 | 2016 |
| Metric | ACMR | CRSP |
|---|---|---|
| Price | $74.98 | $56.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $50.00 | ★ $70.29 |
| AVG Volume (30 Days) | 935.8K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | $74,643,000.00 | ★ $289,590,000.00 |
| Revenue This Year | $29.37 | $807.72 |
| Revenue Next Year | $23.16 | $172.52 |
| P/E Ratio | $50.59 | ★ N/A |
| Revenue Growth | 104.47 | ★ 9169.85 |
| 52 Week Low | $28.46 | $44.12 |
| 52 Week High | $127.19 | $78.48 |
| Indicator | ACMR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 48.23 |
| Support Level | $64.24 | $50.56 |
| Resistance Level | $78.71 | $60.04 |
| Average True Range (ATR) | 4.11 | 2.75 |
| MACD | 1.16 | -0.16 |
| Stochastic Oscillator | 63.00 | 35.16 |
ACM Research Inc supplies capital equipment developed for the semiconductor industry. The company focuses on developing differentiated process solutions that enable effective particle removal, uniform material deposition, and reliable process control for the fabricators of integrated circuits. Its product offerings include wet-cleaning, plating, furnace, PECVD, track, and other front-end processing equipment. Additionally, it develops, manufactures, and sells a range of packaging equipment to wafer assembly and packaging customers. Geographically, the company generates maximum revenue from its customers in Mainland China, and the rest from other regions.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.